Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third Party LMP-CTLs for EBV-Associated Lymphoma
NCT02057445Phase 1Completed
- Sponsor
- New York Medical College
- Start
- Jan 2014
- Primary completion
- Dec 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMP1/2-specific cytotoxic T-lymphocytes in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), lymphoproliferative disorder (LPD) and 1 more (2 arms), sponsored by New York Medical College. Primary endpoints: Safety of giving 3rd party EBV-CTLs at 1 year and Development of third party bank of LMP-specific CTL. Started Jan 2014; status: completed.
02
Drugs
LMP1/2-specific cytotoxic T-lymphocytes
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)lymphoproliferative disorder (LPD)chronic active Epstein-Barr virus infection (CAEBV)
Beyond the preview
Go deeper on NCT02057445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057445.